Cancer Innovation2025，Vol.4Issue(6)：P.127-150,24.DOI:10.1002/cai2.70041
mRNA Cancer Vaccines:From Pandemic Paradigm to Personalized Oncology Therapeutics
Bo Yang 1Juan Liu 2Yang Li 3Xiaoxuan Liu4
作者信息
- 1. Department of Drug Screening and Evaluation,Chia Tai Tianqing Pharmaceutical Group Co.,Ltd,Nanjing,Jiangsu,China School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing,Jiangsu,China
- 2. Hepato-Pancreato-Biliary Center,Beijing Tsinghua Changgung Hospital,Key Laboratory of Digital Intelligence Hepatology(Ministry of Education),School of Clinical Medicine,Tsinghua Medicine,Tsinghua University,Beijing,China
- 3. School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing,Jiangsu,China
- 4. State Key Laboratory of Natural Medicines,Joint International Research Laboratory of Target Discovery and New Drug Innovation(Ministry of Education),Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases,Center of Advanced Pharmaceuticals and Biomaterials,China Pharmaceutical University,Nanjing,Jiangsu,China
- 折叠
摘要
关键词
cancer vaccines/immunotherapy/mRNA分类
医药卫生引用本文复制引用
Bo Yang,Juan Liu,Yang Li,Xiaoxuan Liu..mRNA Cancer Vaccines:From Pandemic Paradigm to Personalized Oncology Therapeutics[J].Cancer Innovation,2025,4(6):P.127-150,24.
